Skip to main content
Erschienen in: Journal of Nuclear Cardiology 4/2017

01.08.2017 | Brief Report

Limitations of Rb-82 weight-adjusted dosing accuracy at low doses

verfasst von: Jonathan B. Moody, PhD, Kerri M. Hiller, BS, CNMT, RT(N), Benjamin C. Lee, PhD, James R. Corbett, MD, Edward P. Ficaro, PhD, Venkatesh L. Murthy, MD, PhD

Erschienen in: Journal of Nuclear Cardiology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Weight-adjusted dosing is important to maintain accurate quantification for dynamic cardiac three-dimensional positron emission tomography (PET). However, the manufacturer of the only Food and Drug Administration approved rubidium-82 (Rb-82) generator (CardioGen-82, Bracco Diagnostics, Inc.) recommends recalibration after each change in dose which is inefficient in a busy clinical PET lab. The objective of this study was to evaluate the accuracy of Rb-82 dosing without this recalibration.

Methods

After daily calibration to either 30 mCi (1110 MBq) or 12 mCi (444 MBq), Rb-82 doses between 6 and 45 mCi (222-1665 MBq) were eluted and measured on an external dose calibrator. This was repeated for four generators at weeks 1, 2, or 4 of the generator cycle. The measurements were compared with values reported by the infusion system.

Results

For requested doses less than 30 mCi, the measured dose was consistently lower than the requested dose, ranging from −3.2 mCi at 25 mCi to −5.5 mCi at 10 mCi. The error exceeded 10% for doses less than or equal to 26 mCi for the 30 mCi calibration. Residual activity in the infusion system dead volume accounted for the discrepancy between requested and delivered doses for calibration to 30 mCi but not 12 mCi.

Conclusions

The CardioGen-82 infusion system is capable of accurate weight-adjusted doses without recalibration for Rb-82 doses as low as 26 mCi when calibrated to 30 mCi. For doses less than 26 mCi, the generator-reported residual activity within the infusion system can be used to correct the delivered dose.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat deKemp RA, Yoshinaga K, Beanlands RSB. Will 3-dimensional PET-CT enable the routine quantification of myocardial blood flow? J Nucl Cardiol. 2007;14:380–97.CrossRef deKemp RA, Yoshinaga K, Beanlands RSB. Will 3-dimensional PET-CT enable the routine quantification of myocardial blood flow? J Nucl Cardiol. 2007;14:380–97.CrossRef
2.
Zurück zum Zitat Cerqueira MD, Allman KC, Ficaro EP, et al. Recommendations for reducing radiation exposure in myocardial perfusion imaging. J Nucl Cardiol. 2010;17:709–18.CrossRef Cerqueira MD, Allman KC, Ficaro EP, et al. Recommendations for reducing radiation exposure in myocardial perfusion imaging. J Nucl Cardiol. 2010;17:709–18.CrossRef
3.
Zurück zum Zitat Dorbala S, Blankstein R, Skali H, et al. Approaches to reducing radiation dose from radionuclide myocardial perfusion imaging. J Nucl Med. 2015;56:592–9.CrossRef Dorbala S, Blankstein R, Skali H, et al. Approaches to reducing radiation dose from radionuclide myocardial perfusion imaging. J Nucl Med. 2015;56:592–9.CrossRef
4.
Zurück zum Zitat Gerber TC, Carr JJ, Arai AE, et al. Ionizing radiation in cardiac imaging. A science advisory from the American Heart Association Committee on Cardiac Imaging of the Council on Clinical Cardiology and Committee on Cardiovascular Imaging and Intervention of the Council on Cardiovascular Radiology and Intervention. Circulation. 2009;119:1056–65.CrossRef Gerber TC, Carr JJ, Arai AE, et al. Ionizing radiation in cardiac imaging. A science advisory from the American Heart Association Committee on Cardiac Imaging of the Council on Clinical Cardiology and Committee on Cardiovascular Imaging and Intervention of the Council on Cardiovascular Radiology and Intervention. Circulation. 2009;119:1056–65.CrossRef
5.
Zurück zum Zitat Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60:e44–164.CrossRef Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60:e44–164.CrossRef
6.
Zurück zum Zitat Fazel R, Gerber TC, Balter S, et al. Approaches to enhancing radiation safety in cardiovascular imaging a scientific statement from the American Heart Association. Circulation. 2014;130:1730–48.CrossRef Fazel R, Gerber TC, Balter S, et al. Approaches to enhancing radiation safety in cardiovascular imaging a scientific statement from the American Heart Association. Circulation. 2014;130:1730–48.CrossRef
7.
Zurück zum Zitat Bracco Diagnostics. CardioGen-82® (Rubidium Rb 82 Generator) Infusion System User Guide. 2013. Bracco Diagnostics. CardioGen-82® (Rubidium Rb 82 Generator) Infusion System User Guide. 2013.
8.
Zurück zum Zitat Tout D, Tonge C, Muthu S, Arumugam P. Assessment of a protocol for routine simultaneous myocardial blood flow measurement and standard myocardial perfusion imaging with rubidium-82 on a high count rate positron emission tomography system. Nucl Med Commun. 2012;33:1202–11.CrossRef Tout D, Tonge C, Muthu S, Arumugam P. Assessment of a protocol for routine simultaneous myocardial blood flow measurement and standard myocardial perfusion imaging with rubidium-82 on a high count rate positron emission tomography system. Nucl Med Commun. 2012;33:1202–11.CrossRef
9.
Zurück zum Zitat Saha GB, Go RT, Macintyre WJ, et al. Use of the 82Sr/82Rb generator in clinical PET studies. Int J Rad Appl Instrum B. 1990;17:763–8.CrossRef Saha GB, Go RT, Macintyre WJ, et al. Use of the 82Sr/82Rb generator in clinical PET studies. Int J Rad Appl Instrum B. 1990;17:763–8.CrossRef
10.
Zurück zum Zitat Gennaro GP, Bergner BC, Haney PS, Kramer RH, Loberg MD. Radioanalysis of 82Rb generator eluates. Int J Rad Appl Instrum. 1987;38:219–25.CrossRef Gennaro GP, Bergner BC, Haney PS, Kramer RH, Loberg MD. Radioanalysis of 82Rb generator eluates. Int J Rad Appl Instrum. 1987;38:219–25.CrossRef
11.
Zurück zum Zitat Renaud J, Huettges J, Gelbach J, Bush E, Port S, deKemp R. Dynamic range is acceptable for myocardial blood flow quantification with the Scintron LSO 3D-PET system. J Nucl Med. 2015;56:1851. Renaud J, Huettges J, Gelbach J, Bush E, Port S, deKemp R. Dynamic range is acceptable for myocardial blood flow quantification with the Scintron LSO 3D-PET system. J Nucl Med. 2015;56:1851.
12.
Zurück zum Zitat Klein R, Adler A, Beanlands RS, deKemp RA. Precision-controlled elution of a 82Sr/82Rb generator for cardiac perfusion imaging with positron emission tomography. Phys Med Biol. 2007;52:659–73.CrossRef Klein R, Adler A, Beanlands RS, deKemp RA. Precision-controlled elution of a 82Sr/82Rb generator for cardiac perfusion imaging with positron emission tomography. Phys Med Biol. 2007;52:659–73.CrossRef
Metadaten
Titel
Limitations of Rb-82 weight-adjusted dosing accuracy at low doses
verfasst von
Jonathan B. Moody, PhD
Kerri M. Hiller, BS, CNMT, RT(N)
Benjamin C. Lee, PhD
James R. Corbett, MD
Edward P. Ficaro, PhD
Venkatesh L. Murthy, MD, PhD
Publikationsdatum
01.08.2017
Verlag
Springer International Publishing
Erschienen in
Journal of Nuclear Cardiology / Ausgabe 4/2017
Print ISSN: 1071-3581
Elektronische ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-016-0531-2

Weitere Artikel der Ausgabe 4/2017

Journal of Nuclear Cardiology 4/2017 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.